03May/13

Sanofi lets go of rights to Regeneron's antibodies in ophthalmology – FierceBiotech


iStockAnalyst

Sanofi lets go of rights to Regeneron’s antibodies in ophthalmology
FierceBiotech
The deal amends the collaboration between Sanofi and Regeneron for the antibodies that target receptors for platelet-derived growth factor (PDGF) and the angiopoietin2 (ANG2) receptor and ligand for eye ailments. Regeneron has agreed to pay Sanofi $10
Regeneron Gains Full Rights to Ophthalmology Antibodies from Sanofi in $65M+ Genetic Engineering News
Regeneron Acquires Rights to Two Families of Novel AntibodiesBenzinga
UPDATE 1-Regeneron raises 2013 Eylea sales view, profit beats StreetReuters UK
RTT News –iStockAnalyst (press release) –Reuters
all 23 news articles »